Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R21 Clinical Trial Optional) | PA 19 201

Frequently Asked Questions (FAQs)

What is the title and funding opportunity number for this NIH grant?

The opportunity is titled "Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R21 Clinical Trial Optional)" and the Funding Opportunity Number is PA-19-201.

What is the main purpose of this funding opportunity?

This FOA supports early-stage, mechanistic research aimed at explaining how sleep disturbances contribute to the development and persistence of chronic pain. The emphasis is on understanding the processes that link sleep disruption to chronic pain onset, worsening, or long-term maintenance.

What kinds of projects are a good fit for this FOA?

Projects that directly test plausible biological, psychological, and/or behavioral mechanisms connecting sleep problems to chronic pain are aligned with the FOA. Studies that integrate methods across disciplines (for example, pairing sleep measures with neuroimaging, immune profiling, hormonal measures, or behavioral sleep manipulation alongside pain processing assessments) fit the intent described.

Are purely descriptive or correlational studies appropriate under this opportunity?

The FOA is framed to prioritize mechanistic studies over projects that only show an association between poor sleep and pain. The focus is on moving beyond correlation to process-level or causal explanations of how sleep disturbances influence chronic pain.

What does "mechanistic research" mean in the context of this FOA?

In this context, mechanistic research means studies designed to test specific pathways or processes through which sleep disruption can affect pain. The FOA highlights that sleep disturbance may influence pain via central nervous system pain processing, stress and hormonal regulation, immune and inflammatory activity, gene expression, cognition and mood, and everyday behaviors that affect pain sensitivity and recovery.

What NIH grant mechanism is used for this opportunity?

This FOA uses the NIH R21 mechanism, which is typically intended for exploratory, potentially high-impact research ideas that may be earlier in development but are grounded in a clear mechanistic hypothesis.

What does "Clinical Trial Optional" mean here?

"Clinical Trial Optional" means applicants may propose studies that include clinical trials if that fits the mechanistic question, but a clinical trial is not required. The FOA allows a broad range of designs, as long as the core objective is understanding how sleep disturbances contribute to chronic pain.

What types of study designs does the FOA allow?

Based on the description, designs may include preclinical mechanistic work, human experimental studies, and pilot clinical intervention trials, provided the central aim is mechanistic understanding of the sleep-to-pain pathway.

Why does the FOA emphasize interdisciplinary research teams?

The FOA underscores that the sleep-pain relationship is complex and may involve multiple interacting systems. NIH explicitly invites teams that combine expertise across fields such as neuroscience, psychology, endocrinology, immunology, genetics, pharmacology, chemistry, physics, behavioral science, clinical practice, caregiving, and other relevant areas.

What kinds of mechanisms or pathways does NIH highlight as relevant?

The FOA points to multiple plausible pathways, including changes in central nervous system pain processing, stress and hormonal regulation, immune and inflammatory activity, gene expression, cognition and mood, and behavioral factors that can influence pain sensitivity and recovery.

Who is the sponsoring agency and what type of program is this?

The sponsoring agency is the National Institutes of Health (NIH). The funding instrument is a grant under a discretionary program, with the listed activity area under Education and Health.

What is the award ceiling for this opportunity?

The listed award ceiling is $200,000, suggesting budgets are expected to be relatively contained and consistent with the exploratory scope of an R21.

When was the FOA created and what closing date is listed?

The FOA record was created on 2019-02-28. The original closing date shown is 2022-05-07.

What CFDA numbers are associated with this opportunity?

The opportunity is associated with multiple CFDA numbers: 93.121, 93.213, 93.273, 93.279, 93.313, 93.361, 93.393, 93.853, and 93.866. This indicates relevance across multiple NIH institutes and programs.

What types of U.S. organizations are eligible to apply?

Eligibility is broad and includes many U.S.-based entities, such as state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses.

Are minority-serving and specialized institutions included in the eligible categories?

Yes. The FOA highlights additional eligible categories including Alaska Native and Native Hawaiian Serving Institutions, AANAPISISs, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).

Can federal agencies or community-based organizations apply?

The eligibility list includes eligible federal agencies as well as faith-based or community-based organizations. The FOA also includes regional organizations, U.S. territories or possessions, and tribal governments that are not federally recognized among highlighted eligible categories.

Can a non-U.S. (foreign) organization apply as the primary applicant?

No. Non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply as the applicant organization.

Are foreign components allowed at all under this FOA?

Yes. While a foreign institution cannot be the primary applicant, foreign components are allowed as defined by the NIH Grants Policy Statement. That means a U.S. applicant may include certain international elements of the research when well-justified and consistent with NIH policy requirements.

What is the overall long-term goal NIH is signaling with this FOA?

The FOA is aimed at strengthening the evidence base for why and how disturbed sleep drives chronic pain, with the longer-term goal of informing better prevention strategies and more targeted treatments.

What is the key thing NIH wants applicants to demonstrate in their proposed research?

The key emphasis is mechanistic clarity: studies should be designed to test credible mechanisms that explain how sleep disturbances contribute to chronic pain, rather than only documenting that the two are related.